Study: A Randomized Controlled Trial Events in Acute Coronary Syndromes: The MIRACL Effects of Atorvastatin on Early Recurrent Ischemic
نویسندگان
چکیده
Correction Contact me if this article is corrected. http://jama.ama-assn.org/cgi/content/full/jama;286/5/536 Correction is appended to this PDF and also available at Citations Contact me when this article is cited. This article has been cited 1012 times. Topic collections Contact me when new articles are published in these topic areas. Infarction System; Randomized Controlled Trial; Cardiovascular Disease/ Myocardial Nutritional and Metabolic Disorders; Lipids and Lipid Disorders; Cardiovascular
منابع مشابه
[Recommendations of the Association of American Medical Colleges on industry support of medical education].
1. SCHWARTZ G, OLSSON A, EZEKOWITZ M, GANZ P, OLIVER M, WATERS D ET AL. Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes: The MIRACL Study: A Randomized Controlled Trial. JAMA 2001; 285: 1711-8. 2. LIEM A, VAN BOVEN A, VEEGER N, WITHAGEN A, ROBLES DE MEDINA R, TIJSSEN J ET AL. Effect of fluvastatin on ischaemia following acute myocardial infarction: a rando...
متن کاملPharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes.
An economic analysis was conducted using clinical outcomes in the MIRACL trial that evaluated high-dose atorvastatin versus placebo for 16 weeks after acute coronary syndrome. The direct cost of atorvastatin was largely offset by the associated decrease in cardiovascular events. The net incremental cost of atorvastatin treatment was 157 dollars/patient with a cost-effectiveness ratio of 4,086 d...
متن کاملEffect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
BACKGROUND Patients with acute coronary syndromes have elevated plasma levels of the proinflammatory, prothrombotic cytokine CD40 ligand (sCD40L). Statins inhibit CD40L signaling in vitro, but there are no prospective studies of statins and sCD40L in acute coronary syndromes. METHODS AND RESULTS We measured sCD40L in subjects with an acute coronary syndrome enrolled in the Myocardial Ischemia...
متن کاملEffects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study.
CONTEXT Patients experience the highest rate of death and recurrent ischemic events during the early period after an acute coronary syndrome, but it is not known whether early initiation of treatment with a statin can reduce the occurrence of these early events. OBJECTIVE To determine whether treatment with atorvastatin, 80 mg/d, initiated 24 to 96 hours after an acute coronary syndrome, redu...
متن کاملThe Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) trial: a new frontier for statins?
The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) Trial tested the hypothesis that intensive lowering of cholesterol with atorvastatin (80 mg/day) initiated 24-96 h after an acute coronary syndrome would, over 4 months, reduce the incidence of the composite endpoint of death, nonfatal infarction, resuscitated cardiac arrest, and recurrent symptomatic myocardial ischemia...
متن کامل